ISSN 1472-4683. Published by i-Base.
Contents. 
Previous page. 
Next page.
On 26 February, the FDA approved a 600mg tablet formulation of the protease inhibitor darunavir (Prezista). Tibotoc, manufacturers of this drug, say that they expect the new formulation to be widely available in the US from May 2008, requiring fewer daily pills than the current 300mg formulation.
Source: FDA list serve/Tibotec PR
Contents. Previous page. Next page.
Top | htb | Home | Order & subscribe | Contact | Site map | Access